| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/14/2005 | WO2005063169A2 Medical lipolysis of fat accumulations |
| 07/14/2005 | WO2005063015A1 Stabilized formulation of ivermerctin feed premix |
| 07/14/2005 | WO2005062947A2 Methods and compositions for identifying rna-binding proteins |
| 07/14/2005 | WO2005053691A3 Nicotine delivery product and method for producing it |
| 07/14/2005 | WO2005051351A3 Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
| 07/14/2005 | WO2005030257A3 Water soluble nanoparticles inclusion complexes |
| 07/14/2005 | WO2005013955A8 Topical composition comprising terbinafine and hydrocortisone |
| 07/14/2005 | WO2005009480A3 Implants containing codrugs |
| 07/14/2005 | WO2004105729A3 Transdermal vaccine delivery device having coated microprotrusions |
| 07/14/2005 | WO2004098535A3 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 07/14/2005 | WO2004091537B1 Process for making gel films |
| 07/14/2005 | WO2004082585A3 Water-soluble conjugates of phenytoin |
| 07/14/2005 | WO2004069179A3 Improved thickened beverages for dysphagia |
| 07/14/2005 | WO2004064769A3 Methods for making and using topical delivery agents |
| 07/14/2005 | WO2004020969A3 Production of nanoparticles having a defined number of ligands |
| 07/14/2005 | WO2004000016A9 Antimicrobial compositions, products and methods employing same |
| 07/14/2005 | US20050154343 Soft tip applicator for relieving mouth pain |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154058 additives in food, cosmetic, pharmaceutical preparations; regioselective esterification of hydroxytyrosol (or oleuropein, oleuropein aglycones) by acylating agent (organic acid or ester) in presence of easily eliminated catalysts; more soluble in lipids; high chemical yields; high potency antioxidant |
| 07/14/2005 | US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis |
| 07/14/2005 | US20050154047 Exert the beneficial effects of melatonin including anti-oxidation, sedation, anesthesia, protection of organs to chemical, infectious and cardiovascular damage, and can be administered in a water-based vehicle |
| 07/14/2005 | US20050154015 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050154013 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/14/2005 | US20050154006 mixture of anticholinergic agents and pyridinecarboxamide's such as 2-(4-fluoro-phenoxy)-N-{4-(1-hydroxy-1-methyl-ethyl)-benzyl}nicotinamide in the form of enantiomers, racemates, solvates or hydrates and optionally mixed with excipients, used for treating respiratory system disorders |
| 07/14/2005 | US20050153999 Pharmaceutical compositions |
| 07/14/2005 | US20050153990 Phosphonate substituted kinase inhibitors |
| 07/14/2005 | US20050153982 Sustained release ranolazine formulations |
| 07/14/2005 | US20050153967 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form |
| 07/14/2005 | US20050153956 Pharmaceutical compositions comprising midazolam in a high concentration |
| 07/14/2005 | US20050153952 Methods for inhibiting sterol absorption |
| 07/14/2005 | US20050153931 Comprises cannabinol, tetrahydrocannabinol and cannabidiol; bioavailability |
| 07/14/2005 | US20050153928 Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
| 07/14/2005 | US20050153920 Ribozymes used as prodrugs |
| 07/14/2005 | US20050153916 Each strand of the siNA molecule is 18 to 23 nucleotides in length; and one strand comprises a nucleotide sequence having sufficient complementarity to telomerase RNA for the siNA molecule to direct cleavage of the RNA via RNA interference. |
| 07/14/2005 | US20050153915 RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
| 07/14/2005 | US20050153914 RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA) |
| 07/14/2005 | US20050153913 Nucleic acid carrier compositions and methods for their synthesis |
| 07/14/2005 | US20050153884 Methods of therapy with thrombin derived peptides |
| 07/14/2005 | US20050153875 Has an iron binding capacity of at least 1.0 mg-per gram of protein, is non-pyrogenic and is pathogen free; preparation by anion exchange chromatography |
| 07/14/2005 | US20050153872 Polypeptide comprising an organism targeting agent such as a pheromone covalently attached to a channel forming moiety such as hemolysin, diphtheria toxin, delta toxin, anthrax toxin, and colicin to treat bacteria, fungi, or viral infections |
| 07/14/2005 | US20050153862 oil absorbing polymer nanospheres coated with water sensitive surface active polymers; cosmetic, personal care, and household products to effectively encapsulate wide range of active ingredients and sensory markers and release them in response to moisture or over an extended period of time |
| 07/14/2005 | US20050153841 Injection formulation |
| 07/14/2005 | US20050153416 Anticancer agents |
| 07/14/2005 | US20050152999 supercritically extracting an herb to obtain an oil extract and a residue;extracting the residue in a water/alcohol liquid mixture to obtain a post-supercritical hydroalcoholic extract; evaporating the water/alcohol liquid to form a powdered extract; mixing the powdered extract with the oil extract. |
| 07/14/2005 | US20050152980 Pharmeutical microparticles |
| 07/14/2005 | US20050152978 Capsule, tablet with enteric, protective coatings; bioavailability |
| 07/14/2005 | US20050152976 Coated particles with prolonged release and tablets containing same |
| 07/14/2005 | US20050152975 Pharmaceutical composition |
| 07/14/2005 | US20050152966 For controlled release of lyophilized probiotic bacterium; compressed tablets |
| 07/14/2005 | US20050152963 Liposome compositions |
| 07/14/2005 | US20050152959 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
| 07/14/2005 | US20050152957 Compositions and delivery systems for administration of a local anesthetic agent |
| 07/14/2005 | US20050152956 Therapy for sexual disorders |
| 07/14/2005 | US20050152913 Process for preapring maytansinol |
| 07/14/2005 | US20050152909 Prostate stem cell antigen (PSCA) tumor antigen for use in diagnosis, prevention and treatment of prostate cancers |
| 07/14/2005 | US20050152894 Antibodies with altered effector functions |
| 07/14/2005 | US20050152883 isolation of ligament cells, then culturing, recovering and implanting the cells into patients |
| 07/14/2005 | US20050152873 Containing an immunogen, a first adjuvant functioning as a directing molecule and a second adjuvant functioning as a stimulant which are chemically distinct |
| 07/14/2005 | US20050152870 Pharmaceutical composition which improves in vivo gene transfer |
| 07/14/2005 | US20050152856 0.5-7% by weight of D,L- alpha -lipoic acid, 0.05-0.5% by weight of coenzyme Q-10 and 0.01-3% by weight of acetyl-L-carnitine hydrochloride; treatment of visible sun injuries caused by processes involving the action of free radicals |
| 07/14/2005 | US20050152848 covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer such as polyethylene glycol; antidiabetic agents |
| 07/14/2005 | US20050152847 Novel formulation |
| 07/14/2005 | US20050152846 Hydrofluoroalkane (HFA) propellant and co-solvents; inhalants; storage stability; deep lung penetration |
| 07/14/2005 | US20050152845 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| 07/14/2005 | DE10361067A1 Medikamentöse Lipolyse von Fettansammlungen Drug lipolysis of fat accumulation |
| 07/14/2005 | DE10131145B4 Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen Composition for cell-specific transfer of drugs |
| 07/14/2005 | CA2551813A1 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 07/14/2005 | CA2551510A1 Stable growth hormone liquid formulation |
| 07/14/2005 | CA2551474A1 Medical lipolysis of fat accumulations |
| 07/14/2005 | CA2551094A1 Methods and compositions for identifying rna-binding proteins |
| 07/14/2005 | CA2550647A1 Injectable phosphatidylcholine preparations |
| 07/14/2005 | CA2550432A1 Pharmaceutical compositions |
| 07/14/2005 | CA2549599A1 Pregabalin composition |
| 07/14/2005 | CA2548951A1 Kinase inhibitor phosphonate conjugates |
| 07/14/2005 | CA2548363A1 Pharmaceutical formulations of bisphosphonates |
| 07/14/2005 | CA2547024A1 Gas-filled microvesicle assembly for contrast imaging |
| 07/14/2005 | CA2545362A1 Assembly of gas-filled microvesicle with active component for contrast imaging |
| 07/13/2005 | EP1552846A2 Use of heparinases to decrease inflammatory responses |
| 07/13/2005 | EP1552833A1 Stable solid preparations |
| 07/13/2005 | EP1552823A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 07/13/2005 | EP1552822A1 Patch |
| 07/13/2005 | EP1552818A1 Release sustaining composition and sustained release preparation |
| 07/13/2005 | EP1552269A2 Formaldehyde-ammonium salt complexes for the stabilization of blood cells |
| 07/13/2005 | EP1552002A2 Aptamer-toxin molecules and methods for using same |
| 07/13/2005 | EP1551977A1 Selective, local activation of members of the tnf ligand family of systemically inactive non-antibody tnf ligand fusion proteins |
| 07/13/2005 | EP1551927A1 Biological active coating components, coatings, and coated surfaces |
| 07/13/2005 | EP1551899A1 Biodegradable phase separated segmented multi block co-polymers |
| 07/13/2005 | EP1551888A1 Terpolymer of maleic acid, maleic anhydride and alkylvinylether |
| 07/13/2005 | EP1551876A2 Antibodies that bind cell-associated ca 125/0722p and methods of use thereof |
| 07/13/2005 | EP1551875A2 Buffered formulations for concentrating antibodies and methods of use thereof |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551763A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 07/13/2005 | EP1551543A1 Compound consisting of precipitated silica and phosphate and use thereof as nutrient intake liquid support and as anticaking agent with nutrient intake |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |
| 07/13/2005 | EP1551459A1 Microbubble compositions, and methods for preparing and using same |
| 07/13/2005 | EP1551458A1 Calixarenes for use as excipient for an active substance |
| 07/13/2005 | EP1551457A1 Liquid dosage compositions of stable nanoparticulate active agents |
| 07/13/2005 | EP1551452A1 Compositions and methods for therapeutic treatment |
| 07/13/2005 | EP1551436A2 Formulations for amylin agonist peptides |
| 07/13/2005 | EP1551426A2 Methods of administering fgf18 |